{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Baltimore&page=76&state=Maryland",
    "query": {
      "state": "Maryland",
      "city": "Baltimore",
      "page": 76
    },
    "page_size": 10
  },
  "pagination": {
    "page": 76,
    "page_size": 10,
    "total_count": 13757,
    "total_pages": 1376,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Baltimore&page=77&state=Maryland&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Baltimore&page=75&state=Maryland&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T16:16:51.225Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02521493",
      "title": "Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Down Syndrome",
        "Myelodysplastic Syndrome",
        "Myeloid Leukemia Associated With Down Syndrome",
        "Myeloproliferative Neoplasm"
      ],
      "interventions": [
        {
          "name": "Asparaginase",
          "type": "DRUG"
        },
        {
          "name": "Asparaginase Erwinia chrysanthemi",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Daunorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Mitoxantrone Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Thioguanine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "91 Days",
        "maximum_age": "3 Years",
        "sex": "ALL",
        "summary": "91 Days to 3 Years"
      },
      "enrollment_count": 280,
      "start_date": "2015-12-23",
      "completion_date": "2027-06-30",
      "has_results": true,
      "last_update_posted_date": "2026-08-19",
      "last_synced_at": "2026-11-19T16:16:51.225Z",
      "location_count": 169,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 131 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02521493"
    },
    {
      "nct_id": "NCT00003352",
      "title": "Combination Chemotherapy in Treating Women With Stage IIIB or Stage IV Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Taxotere",
          "type": "DRUG"
        },
        {
          "name": "Adriamycin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NSABP Foundation Inc",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 89,
      "start_date": "1998-06",
      "completion_date": "2002-12",
      "has_results": false,
      "last_update_posted_date": "2012-12-11",
      "last_synced_at": "2026-11-19T16:16:51.225Z",
      "location_count": 152,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 120 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003352"
    },
    {
      "nct_id": "NCT01748149",
      "title": "Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Pediatric Recurrent/Refractory BRAFV600E-mutant Gliomas"
      ],
      "interventions": [
        {
          "name": "Vemurafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "Up to 25 Years"
      },
      "enrollment_count": 40,
      "start_date": "2014-04-29",
      "completion_date": "2025-07-31",
      "has_results": false,
      "last_update_posted_date": "2025-08-03",
      "last_synced_at": "2026-11-19T16:16:51.225Z",
      "location_count": 20,
      "location_summary": "Los Angeles, California • Oakland, California • San Diego, California + 15 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01748149"
    },
    {
      "nct_id": "NCT07062549",
      "title": "Study of 111In-XYIMSR-01 SPECT/CT in Patients With Metastatic Clear Cell Renal Cell",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Renal Cell Carcinoma (Kidney Cancer)"
      ],
      "interventions": [
        {
          "name": "111In-XYIMSR-01",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2022-01-26",
      "completion_date": "2029-07",
      "has_results": false,
      "last_update_posted_date": "2026-07-21",
      "last_synced_at": "2026-11-19T16:16:51.225Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07062549"
    },
    {
      "nct_id": "NCT07098338",
      "title": "A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Rilvegostomig",
          "type": "DRUG"
        },
        {
          "name": "Ramucirumab",
          "type": "DRUG"
        },
        {
          "name": "Dato-DXd",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 278,
      "start_date": "2025-08-07",
      "completion_date": "2029-04-06",
      "has_results": false,
      "last_update_posted_date": "2026-10-15",
      "last_synced_at": "2026-11-19T16:16:51.225Z",
      "location_count": 6,
      "location_summary": "Santa Monica, California • Santa Rosa, California • Atlanta, Georgia + 3 more",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07098338"
    },
    {
      "nct_id": "NCT02046148",
      "title": "Safety and Immunogenicity of a Trivalent Group B Streptococcus Vaccine in Healthy Pregnant Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "GBS Disease",
        "Streptococcus Agalactiae"
      ],
      "interventions": [
        {
          "name": "GBS trivalent vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 40 Years · Female only"
      },
      "enrollment_count": 75,
      "start_date": "2014-03-18",
      "completion_date": "2016-03-26",
      "has_results": true,
      "last_update_posted_date": "2020-12-29",
      "last_synced_at": "2026-11-19T16:16:51.225Z",
      "location_count": 6,
      "location_summary": "Aurora, Colorado • Baltimore, Maryland • Durham, North Carolina + 3 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02046148"
    },
    {
      "nct_id": "NCT04042025",
      "title": "Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Spinal Muscular Atrophy Type I",
        "Spinal Muscular Atrophy Type II",
        "Spinal Muscular Atrophy Type III",
        "SMA"
      ],
      "interventions": [
        {
          "name": "Onasemnogene Abeparvovec-xioi",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Gene Therapies",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 85,
      "start_date": "2020-02-10",
      "completion_date": "2035-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-24",
      "last_synced_at": "2026-11-19T16:16:51.225Z",
      "location_count": 18,
      "location_summary": "Palo Alto, California • Aurora, Colorado • Chicago, Illinois + 14 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04042025"
    },
    {
      "nct_id": "NCT02210325",
      "title": "Efficacy and Safety Study of Oral Solithromycin Compared to Intramuscular Ceftriaxone Plus Oral Azithromycin in the Treatment of Patients With Gonorrhea",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Uncomplicated Urogenital Gonorrhea"
      ],
      "interventions": [
        {
          "name": "solithromycin",
          "type": "DRUG"
        },
        {
          "name": "ceftriaxone",
          "type": "DRUG"
        },
        {
          "name": "azithromycin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Melinta Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "15 Years and older"
      },
      "enrollment_count": 264,
      "start_date": "2014-08",
      "completion_date": "2017-02-22",
      "has_results": false,
      "last_update_posted_date": "2017-09-11",
      "last_synced_at": "2026-11-19T16:16:51.225Z",
      "location_count": 3,
      "location_summary": "Baltimore, Maryland • Cleveland, Ohio • Toledo, Ohio",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Toledo",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02210325"
    },
    {
      "nct_id": "NCT02049476",
      "title": "Study of the Effectiveness of Ozurdex for the Control of Uveitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Uveitis, Intermediate",
        "Uveitis, Posterior"
      ],
      "interventions": [
        {
          "name": "Dexamethasone pellet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2014-01",
      "completion_date": "2018-06-30",
      "has_results": true,
      "last_update_posted_date": "2019-07-05",
      "last_synced_at": "2026-11-19T16:16:51.225Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02049476"
    },
    {
      "nct_id": "NCT00534781",
      "title": "Achilles Tendinosis Study; Comparison of Radiofrequency to Surgical MicroDebridement",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Achilles Pain",
        "Achilles Tendinosis",
        "Heel Pain"
      ],
      "interventions": [
        {
          "name": "plasma microdebrider",
          "type": "DEVICE"
        },
        {
          "name": "Mechanical Surgical Debridement",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "PROCEDURE"
      ],
      "sponsor": "ArthroCare Corporation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2007-09",
      "completion_date": "2010-09",
      "has_results": false,
      "last_update_posted_date": "2013-07-11",
      "last_synced_at": "2026-11-19T16:16:51.225Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Columbus, Ohio",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00534781"
    }
  ]
}